Registered title, quoted from ClinicalTrials.gov
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06888674, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) post-surgery;
Inclusion criterion 18
Contraception agreement: Fertile males and females of childbearing potential must agree to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. Females of childbearing potential include premenopausal women and women ≤2 years postmenopausal;
Inclusion criterion 12
Serum CA 19-9 level >180 U/mL within 21 days prior to initiating standard postoperative adjuvant therapy;
Exclusion criterion 1
ECOG Performance Status score of 0 or 1;
Inclusion criterion 6
ECOG Performance Status score:Cohort A: 0 or 1;Cohort B: 0-2;
Inclusion criterion 20
Liver function: Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN;
Inclusion criterion 9
Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault formula);
Inclusion criterion 10
HIV antibody-positive;
Exclusion criterion 10
Active hepatitis C (HCV RNA-positive);
Exclusion criterion 12
Active hepatitis B (HBsAg-positive and HBV DNA ≥2000 IU/mL);
Exclusion criterion 13
Pregnancy or lactation;
Exclusion criterion 24
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06888674, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Pre-Screening Phase Inclusion Criteria (for Radical Surgery and Vaccine Preparation):
- Subjects meeting all of the following criteria will enter the pre-screening phase for radical surgery and vaccine preparation:
- Voluntarily sign the informed consent form (ICF);
- Age ≥18 years, regardless of gender;
- Diagnosed with resectable pancreatic cancer as assessed per the 2024 NCCN Clinical Practice Guidelines and willing to undergo radical surgery;
- ECOG Performance Status score of 0 or 1;
- Ability to obtain sufficient fresh tumor tissue samples for whole-exome sequencing (WES) and transcriptome sequencing analysis;
- Normal function of major organs (heart, liver, kidneys):
- Liver function: Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN;
- Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault formula);
- Cardiac function: LVEF ≥50% by echocardiography;
- Contraception agreement: Fertile males and females of childbearing potential must agree to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. Females of childbearing potential include premenopausal women and women ≤2 years postmenopausal;
- Ability to comply with the study protocol and follow-up procedures.
- Formal Screening Phase Inclusion Criteria (for Study Treatment Initiation):
- Subjects meeting all of the following criteria will enter the formal screening phase for study treatment:
- Voluntarily sign the informed consent form (ICF);
- Age ≥18 years, regardless of gender;
- Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) post-surgery;
- Completion of radical resection (R0 or R1) with no evidence of metastatic disease, malignant ascites, or pleural effusion on imaging 4-12 weeks postoperatively;
- ECOG Performance Status score:Cohort A: 0 or 1;Cohort B: 0-2;
- Normal function of major organs (heart, liver, kidneys):
- Contraception agreement: Same as pre-screening criteria;
- Ability to comply with the study protocol and follow-up procedures.
Exclusion Criteria:
Subjects meeting any of the following criteria will be excluded from the study:
- Serum CA 19-9 level >180 U/mL within 21 days prior to initiating standard postoperative adjuvant therapy;
- History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation;
- Concurrent immunosuppressive therapy, defined as regular use of immunosuppressive agents within 4 weeks prior to screening or during the study, including but not limited to:
- Severe asthma requiring systemic corticosteroids (≥10 mg/day prednisone equivalent);
- Active autoimmune disease or immunodeficiency (e.g., rheumatoid arthritis, systemic lupus erythematosus);
- History of primary immunodeficiency;
- Exceptions: Type 1 diabetes, autoimmune hypothyroidism managed with hormone replacement, vitiligo, or psoriasis not requiring systemic therapy;
- Active bacterial/fungal infections requiring systemic treatment, or active/latent tuberculosis (confirmed by interferon-gamma release assay or tuberculin skin test);
- Active viral infections:
- HIV antibody-positive;
- Syphilis (TP antibody-positive with RPR/TRUST confirmation);
- Active hepatitis C (HCV RNA-positive);
- Active hepatitis B (HBsAg-positive and HBV DNA ≥2000 IU/mL);
- Acute viral infections:
- Herpesvirus infection (unless resolved with crusting >4 weeks prior);
- Respiratory viral infection (unless resolved >4 weeks prior);
- Uncontrolled comorbidities:
- Symptomatic congestive heart failure (NYHA Class III/IV);
- Unstable angina or arrhythmia requiring treatment;
- Severe coronary/cerebrovascular disease (e.g., myocardial infarction within 6 months);
- Other conditions deemed exclusionary by the investigator;
- History of drug abuse, psychiatric disorders, or psychosocial factors impairing informed consent or protocol compliance;
- History of severe hypersensitivity to vaccines, biologics, or any component of the study drug;
- Pregnancy or lactation;
- Other conditions judged by the investigator to preclude safe participation.
Quoted from ClinicalTrials.gov, NCT06888674, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06888674, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.